Pharmaceuticals news continually updated from thousands of sources around the net.
2 hrs ago | Reuters
Teva Pharmaceutical Industries Ltd on Thursday told the U.S. Supreme Court that it is willing to post up to a $500 million bond in return for a decision suspending a lower court ruling that would allow generic competitors to go on the market as soon as next month.
Trending on the Topix Network
Prosonix, an innovative specialty pharmaceutical company based in England, has announced a global licensing agreement for its inhaled respiratory products with Mylan Inc. , the Canonsburg-based generic drug giant.
When Wired Magazine featured Birmingham's MedSnap in a story last year, CEO Patrick Hymel probably didn't imagine the article would end up leading to a whole new aspect to the company's business.
Teva Pharmaceutical Industries Ltd said it settled a patent lawsuit with Pfizer Inc, allowing the Israeli drugmaker to launch a generic version of Pfizer's blockbuster painkiller Celebrex in December.
The combination of Akorn and Hi-Tech will transform the Company into a larger, more diversified generic player.
From multivitamins to fish oil, daily pills and powders have become routine for millions around the world.
Mylan Inc. today announced that its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has launched XULANE , the generic version of Janssen Pharmaceuticals Inc.'s ORTHO EVRA * .
State Sen. Hannah-Beth Jackson , D-Santa Barbara, announced on Wednesday that, due to a lack of support from some of her legislative colleagues in the Senate Business, Professions and Economic Development Committee, she is shelving a bill this year to create the nation's first statewide drug take-back program for prescription and over-the-counter ... (more)
Other equities research analysts have also recently issued reports about the stock.
The firm set a "neutral" rating on the stock. TEVA has been the subject of a number of other recent research reports.
Research and Markets: Global Testicular Cancer Drugs Market 2014-2018 With Bristol-Myers Squibb, Hospira, Teva Pharmaceutical Industries & ZIOPHARM Oncology Dominating )--Research and Markets has announced the addition of the "Global Testicular Cancer Drugs Market 2014-201... )--Research and Markets has announced the addition of the "Global ... (more)
The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats.
S&P SmallCap 600 constituent Akorn Inc. is acquiring Hi-Tech Pharmacal Co. in a deal expected to be completed soon.
Does Merck stand a chance? Merck has lagged the hepatitis C race, but the phase 2 results from its oral combination of MK-5172 and MK-8742 in genotype 1 patients are quite impressive.
Mylan received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for this product, which is indicated for the treatment of insomnia.
Today, Analysts Review released its analysts' notes regarding CSX Corp. , Cardinal Health, Inc. , L Brands, Inc. , Discovery Communications, Inc. and CH Robinson Worldwide Inc. .